At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 38 target
Drug / intervention
BL-B01D1drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-B01D1 for Injection in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
In Brief
A Phase 2 clinical trial evaluating BL-B01D1 for Gynecological Malignant Tumor and Solid Tumor. Currently recruiting, targeting 38 participants across 1 site.
Detailed Summary
A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGynecological Malignant Tumor, Solid Tumor
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 2Recruiting
20242025202620272028
First PostedApr 2023
Enrollment StartJun 2023
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedApr 7, 2023
Enrollment StartJun 25, 2023
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 3.4 yearsPosted 3.2 years agoPrimary completion in 5 months
Interventions
BL-B01D1drug
Administration by intravenous infusion